Pharmaceuticals · NYSE
TEVATeva Pharmaceutical Industries Ltd
- Last close
- $44.50 +1.9%
- 52-week range
- $37.00 to $44.56
- Market cap
- $51.9B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own history since 2026
Where each multiple sits today inside its own range since 2026, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 103x
- Earnings yield
- 1.0%
- Price / sales
- 3.7x
- Price / book
- 6.5x
- Price / operating cash flow
- 29.3x
- EV / EBITDA
- 21.4x
- EV / sales
- 3.7x
- Free cash flow yield
- 2.4%
Profitability
- Gross margin
- 65.8%
- Operating margin
- 10.2%
- Net margin
- 3.6%
- Return on equity
- 6.3%
- Return on capital
- 9.4%
Growth per year
- Revenue, 3 years
- +5.0%
- Revenue, 5 years
- +0.7%
- Revenue, 9 years
- -2.6%
- EPS, 3 years
- n/aNot meaningful (a loss in the window)
Balance sheet
- Cash and investments
- $4.08B
- Total debt
- $4.04B
- Net cash
- $47.0M
- Debt / equity
- 0.51x
- Current ratio
- 0.95x
Shares and dividend
- Shares outstanding
- 1.17B
- Share count, 5 years
- +6.2%
- Beta, 1 year
- n/aNot enough price history
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
License went from 1% to 4% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Product | $14.6B | 84.6% | +4% |
| Distribution Service | $1.55B | 9.0% | -2% |
| License | $678M | 3.9% | +292% |
| Product and Service Other | $423M | 2.5% | -43% |
Pharmaceuticals peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| LLY ELI LILLY & Co | $1.36T | +46% | n/a | 46.8x | 15.7x | 60th percentile |
| JNJ Johnson & Johnson | $688B | +8% | n/a | 43.4x | 6.9x | 90th percentile |
| MRK Merck & Co., Inc. | $364B | +5% | n/a | 152x | 5.4x | 98th percentile |
| PFE Pfizer Inc | $165B | +1% | n/a | 41.2x | 2.6x | 97th percentile |
| BMY Bristol Myers Squibb Co | $130B | +4% | n/a | 14.1x | 2.6x | 13th percentile |
| TEVA Teva Pharmaceutical Industries Ltd | $51.9B | -16% | 10.2% | 103x | 3.7x | Not enough history |
The company
- Sector
- Health Care
- Industry
- Pharmaceuticals
- CEO
- Richard Francis
- Employees
- 42,535 (as of 2018)
- Founded
- 1901
- Headquarters
- Tel Aviv
- Fiscal year ends
- December
- Website
- teva.co.il
What it does
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about TEVA.